These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 33581289)

  • 1. Carbonyl reduction pathway in hepatic in vitro metabolism of anthracyclines: Impact of structure on biotransformation rate.
    Piska K; Jamrozik M; Koczurkiewicz-Adamczyk P; Bucki A; Żmudzki P; Kołaczkowski M; Pękala E
    Toxicol Lett; 2021 May; 342():50-57. PubMed ID: 33581289
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aldo-keto reductase 1C3 (AKR1C3): a missing piece of the puzzle in the dinaciclib interaction profile.
    Novotná E; Büküm N; Hofman J; Flaxová M; Kouklíková E; Louvarová D; Wsól V
    Arch Toxicol; 2018 Sep; 92(9):2845-2857. PubMed ID: 29992508
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Roscovitine and purvalanol A effectively reverse anthracycline resistance mediated by the activity of aldo-keto reductase 1C3 (AKR1C3): A promising therapeutic target for cancer treatment.
    Novotná E; Büküm N; Hofman J; Flaxová M; Kouklíková E; Louvarová D; Wsól V
    Biochem Pharmacol; 2018 Oct; 156():22-31. PubMed ID: 30077642
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Buparlisib is a novel inhibitor of daunorubicin reduction mediated by aldo-keto reductase 1C3.
    Bukum N; Novotna E; Morell A; Hofman J; Wsol V
    Chem Biol Interact; 2019 Apr; 302():101-107. PubMed ID: 30703376
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anthracyclines and their metabolism in human liver microsomes and the participation of the new microsomal carbonyl reductase.
    Skarka A; Skarydová L; Stambergová H; Wsól V
    Chem Biol Interact; 2011 May; 191(1-3):66-74. PubMed ID: 21185270
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Carbonyl reduction of warfarin: Identification and characterization of human warfarin reductases.
    Malátková P; Sokolová S; Chocholoušová Havlíková L; Wsól V
    Biochem Pharmacol; 2016 Jun; 109():83-90. PubMed ID: 27055738
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In Silico and In Vitro Assessment of Carbonyl Reductase 1 Inhibition Using ASP9521-A Potent Aldo-Keto Reductase 1C3 Inhibitor with the Potential to Support Anticancer Therapy Using Anthracycline Antibiotics.
    Jamrozik M; Piska K; Bucki A; Koczurkiewicz-Adamczyk P; Sapa M; Władyka B; Pękala E; Kołaczkowski M
    Molecules; 2023 Apr; 28(9):. PubMed ID: 37175180
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anthracycline resistance mediated by reductive metabolism in cancer cells: the role of aldo-keto reductase 1C3.
    Hofman J; Malcekova B; Skarka A; Novotna E; Wsol V
    Toxicol Appl Pharmacol; 2014 Aug; 278(3):238-48. PubMed ID: 24832494
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reduction of doxorubicin and oracin and induction of carbonyl reductase in human breast carcinoma MCF-7 cells.
    Gavelová M; Hladíková J; Vildová L; Novotná R; Vondrácek J; Krcmár P; Machala M; Skálová L
    Chem Biol Interact; 2008 Oct; 176(1):9-18. PubMed ID: 18755171
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Carbonyl reductase 1 is a predominant doxorubicin reductase in the human liver.
    Kassner N; Huse K; Martin HJ; Gödtel-Armbrust U; Metzger A; Meineke I; Brockmöller J; Klein K; Zanger UM; Maser E; Wojnowski L
    Drug Metab Dispos; 2008 Oct; 36(10):2113-20. PubMed ID: 18635746
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Two nonsynonymous single nucleotide polymorphisms of human carbonyl reductase 1 demonstrate reduced in vitro metabolism of daunorubicin and doxorubicin.
    Bains OS; Karkling MJ; Grigliatti TA; Reid RE; Riggs KW
    Drug Metab Dispos; 2009 May; 37(5):1107-14. PubMed ID: 19204081
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synergistic anticancer activity of doxorubicin and piperlongumine on DU-145 prostate cancer cells - The involvement of carbonyl reductase 1 inhibition.
    Piska K; Koczurkiewicz P; Wnuk D; Karnas E; Bucki A; Wójcik-Pszczoła K; Jamrozik M; Michalik M; Kołaczkowski M; Pękala E
    Chem Biol Interact; 2019 Feb; 300():40-48. PubMed ID: 30611789
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of the Canine Anthracycline-Metabolizing Enzyme Carbonyl Reductase 1 (cbr1) and the Functional Isoform cbr1 V218.
    Ferguson DC; Cheng Q; Blanco JG
    Drug Metab Dispos; 2015 Jul; 43(7):922-7. PubMed ID: 25918240
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Carbonyl Reductase 1 Plays a Significant Role in Converting Doxorubicin to Cardiotoxic Doxorubicinol in Mouse Liver, but the Majority of the Doxorubicinol-Forming Activity Remains Unidentified.
    Breysse DH; Boone RM; Long CM; Merrill ME; Schaupp CM; White CC; Kavanagh TJ; Schmidt EE; Merrill GF
    Drug Metab Dispos; 2020 Mar; 48(3):187-197. PubMed ID: 31955137
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human dehydrogenase/reductase SDR family member 11 (DHRS11) and aldo-keto reductase 1C isoforms in comparison: Substrate and reaction specificity in the reduction of 11-keto-C
    Endo S; Morikawa Y; Kudo Y; Suenami K; Matsunaga T; Ikari A; Hara A
    J Steroid Biochem Mol Biol; 2020 May; 199():105586. PubMed ID: 31926269
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aldo-keto reductase 1C2 fails to metabolize doxorubicin and daunorubicin in vitro.
    Takahashi RH; Bains OS; Pfeifer TA; Grigliatti TA; Reid RE; Riggs KW
    Drug Metab Dispos; 2008 Jun; 36(6):991-4. PubMed ID: 18322072
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of new lipophilic chelators on the activities of cytosolic reductases and P450 cytochromes involved in the metabolism of anthracycline antibiotics: studies in vitro.
    Schröterová L; Kaiserová H; Baliharová V; Velík J; Gersl V; Kvasnicková E
    Physiol Res; 2004; 53(6):683-91. PubMed ID: 15588138
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metabolic carbonyl reduction of anthracyclines - role in cardiotoxicity and cancer resistance. Reducing enzymes as putative targets for novel cardioprotective and chemosensitizing agents.
    Piska K; Koczurkiewicz P; Bucki A; Wójcik-Pszczoła K; Kołaczkowski M; Pękala E
    Invest New Drugs; 2017 Jun; 35(3):375-385. PubMed ID: 28283780
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Naturally occurring variants of human aldo-keto reductases with reduced in vitro metabolism of daunorubicin and doxorubicin.
    Bains OS; Grigliatti TA; Reid RE; Riggs KW
    J Pharmacol Exp Ther; 2010 Dec; 335(3):533-45. PubMed ID: 20837989
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adipocytes Sequester and Metabolize the Chemotherapeutic Daunorubicin.
    Sheng X; Parmentier JH; Tucci J; Pei H; Cortez-Toledo O; Dieli-Conwright CM; Oberley MJ; Neely M; Orgel E; Louie SG; Mittelman SD
    Mol Cancer Res; 2017 Dec; 15(12):1704-1713. PubMed ID: 29117945
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.